Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anneke Geurts-Moespot

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Clinical Chemistry|February 1, 2005
Concerns about mammaglobin assaysPaul N Span, Nicolai I Grebenchtchikov, Anneke Geurts-Moespot, et al.
Seminars in Cancer Biology|June 1, 2014
Therapeutic targeting of autophagy in cancer. Part I: molecular pathways controlling autophagyAnika Nagelkerke, Fred C G J Sweep, Anneke Geurts-Moespot, et al.
Seminars in Cancer Biology|June 17, 2014
Therapeutic targeting of autophagy in cancer. Part II: pharmacological modulation of treatment-induced autophagyAnika Nagelkerke, Johan Bussink, Anneke Geurts-Moespot, et al.
Cancer|September 5, 2002
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapyFabrice Branle, Florence Lefranc, Isabelle Camby, et al.
Journal of the Society for Gynecologic Investigation|February 21, 2003
Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levelsFrédéric Amant, Erik Huys, Anneke Geurts-Moespot, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2020
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancerKarin Abbink, Petra L M Zusterzeel, Anneke Geurts-Moespot, et al.
Oncology|August 3, 2007
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cellsLisa D Sprague, Karin Mengele, Daniela Schilling, et al.
BMC Cancer|August 1, 2007
Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell linesDaniela Schilling, Christine Bayer, Anneke Geurts-Moespot, et al.
American Journal of Obstetrics and Gynecology|October 22, 2002
Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsiaEva Maria Roes, C G Fred Sweep, Chris M Thomas, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 5, 2006
Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluidAnna C Verkleij-Hagoort, Nicolette T Ursem, Wim C Hop, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Clinical Chemistry|February 1, 2005
Concerns about mammaglobin assaysPaul N Span, Nicolai I Grebenchtchikov, Anneke Geurts-Moespot, et al.
Seminars in Cancer Biology|June 1, 2014
Therapeutic targeting of autophagy in cancer. Part I: molecular pathways controlling autophagyAnika Nagelkerke, Fred C G J Sweep, Anneke Geurts-Moespot, et al.
Seminars in Cancer Biology|June 17, 2014
Therapeutic targeting of autophagy in cancer. Part II: pharmacological modulation of treatment-induced autophagyAnika Nagelkerke, Johan Bussink, Anneke Geurts-Moespot, et al.
Cancer|September 5, 2002
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapyFabrice Branle, Florence Lefranc, Isabelle Camby, et al.
Journal of the Society for Gynecologic Investigation|February 21, 2003
Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levelsFrédéric Amant, Erik Huys, Anneke Geurts-Moespot, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2020
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancerKarin Abbink, Petra L M Zusterzeel, Anneke Geurts-Moespot, et al.
Oncology|August 3, 2007
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cellsLisa D Sprague, Karin Mengele, Daniela Schilling, et al.
BMC Cancer|August 1, 2007
Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell linesDaniela Schilling, Christine Bayer, Anneke Geurts-Moespot, et al.
American Journal of Obstetrics and Gynecology|October 22, 2002
Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsiaEva Maria Roes, C G Fred Sweep, Chris M Thomas, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 5, 2006
Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluidAnna C Verkleij-Hagoort, Nicolette T Ursem, Wim C Hop, et al.
Pageof 4